David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Fossil Group
FOSL
$329M
| $17.2M | 0.02% |
1,251,623
+261,287
| +26% | +$4.16M |
|
777
Regions Financial
RF
$26.1B
| $17.2M | 0.02% |
+1,212,760
| New | +$18.6M |
|
|
NATI
778
DELISTED
National Instruments Corp
NATI
| $17.1M | 0.02% |
385,806
+271,188
| +237% | +$12.3M |
|
779
CALL
Berkshire Hathaway Class B
BRK.B
$1.08T
| $17.1M | 0.02% |
85,000
+30,000
| +55% | +$6.06M |
|
|
SGI
780
Somnigroup International
SGI
$13.5B
| $17M | 0.02% |
1,182,368
+1,115,816
| +1,677% | +$15.1M |
|
781
Charles River Laboratories
CRL
$14.3B
| $17M | 0.02% |
117,098
+16,011
| +16% | +$2.1M |
|
|
DVAX
782
DELISTED
Dynavax Technologies
DVAX
| $17M | 0.02% |
2,326,712
+32,192
| +1% | +$315K |
|
783
Assured Guaranty
AGO
$3.26B
| $17M | 0.02% |
382,325
-370,123
| -49% | -$15.4M |
|
784
Sun Communities
SUI
$15B
| $16.9M | 0.02% |
142,977
-121,449
| -46% | -$13.5M |
|
785
Sony
SONY
$142B
| $16.8M | 0.02% |
1,987,990
-396,085
| -17% | -$3.71M |
|
786
PUT
Home Depot
HD
$336B
| $16.7M | 0.02% |
87,000
-158,900
| -65% | -$29.1M |
|
787
Baxter International
BAX
$13.7B
| $16.7M | 0.02% |
205,079
-132,950
| -39% | -$9.68M |
|
788
PUT
Freeport-McMoran
FCX
$112B
| $16.7M | 0.02% |
1,292,800
-762,200
| -37% | -$9.22M |
|
789
Ford
F
$55.5B
| $16.6M | 0.02% |
1,893,957
-3,732,150
| -66% | -$32.1M |
|
|
SEM
790
DELISTED
Select Medical
SEM
| $16.6M | 0.02% |
2,182,428
+1,229,123
| +129% | +$9.88M |
|
791
Stellantis
STLA
$19.7B
| $16.6M | 0.02% |
1,115,183
-360,497
| -24% | -$5.54M |
|
792
Rapid7
RPD
$822M
| $16.6M | 0.02% |
327,034
+155,068
| +90% | +$6.64M |
|
793
PUT
Regeneron Pharmaceuticals
REGN
$85.3B
| $16.5M | 0.02% |
40,300
-112,100
| -74% | -$46.2M |
|
794
PUT
Biogen
BIIB
$32.2B
| $16.5M | 0.02% |
70,000
-104,300
| -60% | -$32.8M |
|
|
AVNS
795
DELISTED
Avanos Medical
AVNS
| $16.5M | 0.02% |
387,603
+41,508
| +12% | +$1.86M |
|
|
NVTA
796
DELISTED
Invitae Corporation
NVTA
| $16.5M | 0.02% |
702,499
+43,878
| +7% | +$774K |
|
797
Clorox
CLX
$13B
| $16.4M | 0.02% |
102,458
+99,758
| +3,695% | +$15.5M |
|
|
NSTG
798
DELISTED
NanoString Technologies, Inc.
NSTG
| $16.4M | 0.02% |
686,313
+351,638
| +105% | +$8.08M |
|
799
Credicorp
BAP
$30.2B
| $16.4M | 0.02% |
68,344
-27,473
| -29% | -$6.55M |
|
800
CALL
Align Technology
ALGN
$11.3B
| $16.4M | 0.02% |
57,600
-50,900
| -47% | -$12.1M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.